NASDAQ$AKYA
Akoya Biosciences Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Akoya's first quarter performance demonstrated continued adoption of Codex and Phenoptics solutions, with strong financial results and progress across metrics.
Akoya Biosciences reported total revenue of $12.2 million for the first quarter of 2021, compared to $11.0 million in the first quarter of 2020. Product revenue was $10.0 million, with instrument revenue at $6.8 million and reagent revenue at $2.5 million.
- Total revenue for the first quarter of 2021 was $12.2 million, compared to $11.0 million in the first quarter of 2020.
- Product revenue was $10.0 million in the first quarter of 2021, compared to $8.9 million in the prior year period.
- Instrument revenue was $6.8 million in the first quarter 2021, compared to $6.7 million in the first quarter 2020.
- Reagent revenue was $2.5 million in the first quarter 2021, compared to $2.1 million in the first quarter 2020.
Headline financials
Revenue & EPS history
Akoya · Revenue · Quarterly
$12.2M
Revenue by segment
Akoya · $12.2M total across 2 segments · Q1 2021
- Product revenue$10M+12.4%82.0%
- Service and other revenue$2.2M+4.8%18.0%
Forward guidance
Akoya expects full year 2021 revenue to be at least $52.0 million. The second quarter of 2021 is expected to have revenue growth of approximately 45% over the prior year quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports
-3.7%
Avg return
Earnings day
-8.6%
Avg return
5 days after
-17.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+13.7%
Q4 2021
Best reaction
-31.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | — | — | — | |
| Q1 2025 | +1.0% | +24.8% | +23.8% | |
| Q4 2025 | +3.8% | +9.2% | -30.7% | |
| Q3 2024 | -24.9% | -33.2% | -29.5% | |
| Q2 2024 | -9.5% | -0.9% | +5.5% | |
| Q1 2024 | -31.9% | -35.1% | -50.0% | |
| Q4 2023 | -15.4% | -17.1% | -28.1% | |
| Q3 2023 | +10.0% | +6.9% | +16.4% | |
| Q2 2023 | +0.9% | -6.5% | -23.9% | |
| Q1 2023 | -2.5% | -17.1% | -18.8% | |
| Q4 2022 | -7.3% | -17.2% | -36.6% | |
| Q3 2022 | -15.1% | — | — | |
| Q2 2022 | +5.0% | — | — | |
| Q1 2022 | -11.9% | — | — | |
| Q4 2021 | +13.7% | — | — | |
| Q3 2020 | +1.5% | — | — | |
| Q3 2021 | +0.2% | — | — | |
| Q2 2021 | -0.1% | — | — | |
| Q4 2020 | +9.5% | — | — | |
| Q1 2021 | +2.3% | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro